Locoregional recurrence after neoadjuvant versus adjuvant chemotherapy based on tumor subtypes in patients with early-stage breast cancer: A multi-institutional retrospective cohort study
Jong-Ho Cheun(Seoul National University), Wonshik Han(Seoul National University), Ki‐Tae Hwang(Seoul National University), Han‐Byoel Lee(Seoul National University Hospital), Youngji Kwak(Samsung Medical Center), Ji-Jung Jung, Hyeong‐Gon Moon(Seoul National University), Yeon Hee Park(Samsung Medical Center), Hong Kyu Kim(Seoul National University), Kyung-Hun Lee(Seoul National University), Eunhye Kang(Seoul National University)
Cited by 3
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Galectin‐1 expression in cancer‐associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer
|International Journal of Cancer|2007|168
A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study
|Breast Cancer Research|2012|139
Gene Expression Profiling of Breast Cancer Brain Metastasis
|Scientific Reports|2016|76